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24-y-old woman was admitted to
the emergency department having
had a generalized seizure (acute loss
of consciousness, convulsive movements of
her arms and legs, and confusion on regain-
ing consciousness). She was on the sixth day
of treatment with 300 mg daily of slow-
release bupropion (Zyban SR) as an aid to
smoking cessation. She had a past medical
history of tonsillectomy and hay fever, for
which she was taking budesonide nasal
drops (two drops daily, each drop 200
mcg). She was on no other medication. There
was no history of head trauma, liver disease,
or alcohol withdrawal. Clinical examination,
including neurological examination, was nor-
mal. The patient’s weight was 48 kg. Her
blood pressure was 130/80 mm Hg. Electro-
cardiogram showed a sinus tachycardia at
102 beats per minute. Radiography of the
skull and a computed tomography scan of
the brain without contrast were both normal.
The patient’s blood glucose, urea, electro-
lytes, and liver function tests were all normal.
Her serum calcium was 2.01 mmol/l (normal
range, 2.0–2.6 mmol/l) and her hemoglobin
was 116 g/l (normal range, 120–140 g/l). The
bupropion was discontinued, and the patient
recovered without any further seizures or
other neurological sequelae.
Case Discussion
Bupropion for Smoking Cessation
Originally developed as an antidepressant,
bupropion has more recently been licensed
in many countries as an aid to smoking
cessation. It came onto the Mauritian market
as a smoking cessation aid in November 2003.
The British National Formulary (www.
bnf.org) recommends starting the drug one
to two weeks before the target smoking stop
date, initially at a dose of 150 mg daily for 6 d
and then 150 mg twice daily. The maximum
period of treatment is 7–9 wk; treatment
should be discontinued if abstinence is not
achieved by 7 wk.
The efﬁcacy of bupropion as an aid to
smoking cessation has been shown in
randomized, double-blind, placebo-con-
trolled trials [1,2]. But there have also been
reports of death, seizure, serum sickness,
generalized acute urticaria, myocardial in-
farction, and psychosis in people taking the
drug [3,4,5,6,7]. Our report is of a woman who
had a generalized seizure on the sixth day of
treatment with bupropion; she had no other
risk factors for seizures.
Contraindications to Bupropion
To reduce the risk of seizures, the drug
should not be given to patients with a current
seizure disorder or any history of seizures,
with a current or previous diagnosis of
bulimia or anorexia nervosa, with a known
central nervous system tumour, or to those
experiencing abrupt withdrawal from alcohol
or benzodiazepines [8,9].
The United Kingdom Medicines Control
Agency states that bupropion must not be
prescribed in patients with other risk factors
for seizures, unless there is a compelling
clinical justiﬁcation for which the potential
medical beneﬁt of smoking cessation out-
weighs the potential increased risk of seizure
[8]. Predisposing risk factors for seizure
include the following: concomitant use of
medications known to lower seizure thresh-
old (including antipsychotics, antidepres-
sants, antimalarials, tramadol, theophylline,
systemic steroids, quinolones, and sedating
antihistamines), history of head trauma,
diabetes treated with hypoglycemics or in-
sulin, history of alcohol abuse, and use of
stimulants or anorectic products [8].
The Seizure Risk
Bupropion is associated with a dose-related
risk of seizure. The Medicines Control
Agency states that the incidence of seizures
is one in 1,000 based on doses up to the
maximum recommended daily dose of 300
mg per day [8]. The seizure risk may be
reduced by taking no more than 150 mg (1
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Open access, freely available online PLoS MEDICINEpill) at a time and, if taking two daily doses of 150 mg each
(two pills per day), ensuring that doses are taken at least 8 h
apart (see www.bnf.org).
Up to 24 July 2002, in the UK there were 184 reports of
seizures suspected as being associated with the use of
bupropion [8]. In about half of the reports, patients had a
past history of seizures and/or risk factors for their
occurrence.
The Presenting Case
In the case we have presented, the patient had no current or
previous history of seizure disorders, bulimia, or anorexia
nervosa. She was on the sixth day of treatment with
bupropion, taking 300 mg per day in two separate doses.
She had no other predisposing risk factors for seizure. In
particular she was taking no prescription medications, or
over-the-counter medications (such as those containing
ephedrine products) that are known to lower the seizure
threshold. While systemic steroids can lower the seizure
threshold, systemic absorption of the nasal steroid drops the
patient was taking is an extremely unlikely cause for her
seizure (she was not taking a high dose of high-strength
drops). Her weight (48 kg) may have been an important
factor, since bupropion reaches higher plasma levels in
smaller individuals—indeed clinical trials of the drug have
generally excluded patients weighing under 100 lb (about 45
kg) [2].
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Learning Points
 This case report is a useful reminder to clinicians that
bupropion is associated with a dose-dependent risk of seizures.
 In about half of the reports of seizure associated with
bupropion, there was a past history of seizures and/or risk
factors for their occurrence.
 It is extremely important to adequately assess seizure risk
before prescribing bupropion.
 Patients should be made aware of the possible adverse effects
of the drug.
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